Skip to main content

Research Repository

Advanced Search

Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial

Pilcher, Janine; Patel, Mitesh; Pritchard, Alison; Thayabaran, Darmiga; Ebmeier, Stefan; Shaw, Dominick; Black, Peter; Braithwaite, Irene; Weatherall, Mark; Beasley, Richard

Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial Thumbnail


Authors

Janine Pilcher

Mitesh Patel

Alison Pritchard

Darmiga Thayabaran

Stefan Ebmeier

Dominick Shaw

Peter Black

Irene Braithwaite

Mark Weatherall

Richard Beasley



Abstract

Asthma mortality surveys report delays in seeking medical review and overuse of beta-agonist therapy as factors contributing to a fatal outcome. However, the strength of these associations is limited because many asthma deaths are unwitnessed. We undertook a secondary analysis of data from a 24-week randomised controlled trial of 303 patients with high-risk asthma, randomised to combination budesonide/formoterol inhaler according to a single maintenance and reliever therapy regimen or fixed dose budesonide/formoterol with salbutamol as reliever (Standard) regimen. Medication use was measured by electronic monitors. The thresholds for high, marked and extreme beta-agonist use days were defined in the single maintenance and reliever therapy arm as: >8, >12 and >16 actuations of budesonide/formoterol in excess of four maintenance doses, respectively; and in the Standard arm as: >16, >24 and >32 actuations of salbutamol, respectively. Whether a medical review was obtained within 48 h of an overuse episode was determined by review of data collected during the study by participant report. The mean (standard deviation) proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48 h was 0·94 (0·20), 0·94(0·15) and 0·94(0·17), and 0·92(0·19), 0·90(0·26) and 0·94(0·15) for single maintenance and reliever therapy and Standard regimens, respectively. In at least 90% of days, in which beta-agonist overuse occurred, patients did not obtain medical review within 48 h of beta-agonist overuse, regardless of the magnitude of overuse or the inhaled corticosteroid/long-acting beta-agonist regimen.

Citation

Pilcher, J., Patel, M., Pritchard, A., Thayabaran, D., Ebmeier, S., Shaw, D., …Beasley, R. (2017). Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial. npj Primary Care Respiratory Medicine, 27(1), https://doi.org/10.1038/s41533-017-0032-z

Journal Article Type Article
Acceptance Date Mar 27, 2016
Online Publication Date May 11, 2017
Publication Date 2017-12
Deposit Date May 30, 2017
Publicly Available Date May 30, 2017
Journal npj Primary Care Respiratory Medicine
Electronic ISSN 2055-1010
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 27
Issue 1
DOI https://doi.org/10.1038/s41533-017-0032-z
Public URL https://nottingham-repository.worktribe.com/output/860306
Publisher URL https://www.nature.com/articles/s41533-017-0032-z

Files





You might also like



Downloadable Citations